Skip to main content
Premium Trial:

Request an Annual Quote

Variagenics Reports Higher Losses, Tiny Revenues for Q2

NEW YORK, Aug. 6-Variagenics' losses nearly doubled and its revenues dwindled to only $200,000 in the second quarter of 2002, the company said today.

 

The slide was substantial from the second quarter of 2001, when the company reported $900,000 in revenues.

 

Net losses for the quarter, including a nearly $2 million restructuring charge and $1.3 million in equity compensation, totaled $9.8 million or 42 cents per share. In the equivalent period of 2001, Variagenics reported a loss of $5.6 million or 24 cents per share.

 

R&D  expenses for the period climbed from $4 million in the second quarter of last year to $5.2 million in the equivalent period this year.

 

The company said it held $64 million in cash, cash equivalents and short-term marketable securities as of June 30.

 

Variagenics expects that its restructuring, which was put in place in May 2002, will lower its net cash burn rate to about $4 million per quarter by the fourth quarter of this year.

 

For more information, see the press release.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.